Patents by Inventor Chenggang Zhang

Chenggang Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210295227
    Abstract: This invention involves a multi-energy distributed transaction and smart contract design method based on the Ethereum private chain. This method includes the following steps: 1) Setting the genesis node of the smart contract as an administrator node, while other nodes as user nodes; 2) Distinguishing system functions and account permissions between administrator nodes and user nodes. Only administrator nodes can add or delete the types of tradable energy in the blockchain through the energy switch function; 3) The user realizes multiple energy transactions at the same time, and the smart contract matches the information released by users based on the market supply and demand situation. This invention can effectively solve the problems of the centralization of the current energy trading system and insufficient security protection. At the same time, it provides an effective solution to the current limited development of blockchain technology in the field of multi-energy trading.
    Type: Application
    Filed: November 17, 2020
    Publication date: September 23, 2021
    Inventors: Tao DING, Jiangbin DONG, Chenggang MU, Ming QU, Ke'er NING, Xiaobo Dong, Jie QI, Xiaomeng ZHANG, Yuankang HE, Tian'en CHEN, Yongqing WANG, Jian LIU
  • Publication number: 20210263246
    Abstract: Disclosed are a dual-carrier integrated optical device and a photoelectric module. The optical device comprises: an encapsulation unit, and a ceramic substrate and two independent carrier assemblies arranged in the encapsulation unit. Every carrier assembly comprises a DWDM active chip arranged on the first heat sink, a first heat sink arranged on the independent control element, and an independent control element for adjusting the temperature of the DWDM active chip to adjust an output wavelength of the DWDM active chip. The DWDM active chip and the independent control element are respectively connected to the ceramic substrate. According to the characteristic that the wavelength of the active chip will shift with the temperature, an output laser wavelength of each active chip is independently controlled by means of the independent control element, which achieves higher wavelength stability and can realize optical signal transmission at different rates.
    Type: Application
    Filed: December 25, 2018
    Publication date: August 26, 2021
    Applicant: Wuhan Telecommunication Devices Co., Ltd
    Inventors: Yangyang Yue, Xiaoping Song, Chengpeng Fu, Jian Li, Qinlian Bu, Hongchun Xu, Wuping Zhang, Chenggang Liu
  • Patent number: 11091485
    Abstract: Provided is an imidazo[1?,2?:1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong activity.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: August 17, 2021
    Assignee: SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
    Inventors: Bin Liu, Hang Cheng, Weiyan Xiong, Chenggang Zhang, Chengzhi Yu
  • Publication number: 20210147424
    Abstract: A 1H-pyrazolo[4,3-H]quinazoline compound represented by formula (I) can be used for treating cell proliferation dysfunction, and is an broad-spectrum and strongly-active inhibitor for a cell cyclin-dependent kinase (CDK).
    Type: Application
    Filed: August 10, 2018
    Publication date: May 20, 2021
    Inventors: Bin Liu, Hang Cheng, Weiyan Xiong, Chenggang Zhang, Chengzhi Yu
  • Publication number: 20200270251
    Abstract: Provided is an imidazo[1?;2?:1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong activity.
    Type: Application
    Filed: May 21, 2018
    Publication date: August 27, 2020
    Inventors: Bin Liu, Hang Cheng, Weiyan Xiong, Chenggang Zhang, Chengzhi Yu
  • Publication number: 20180200284
    Abstract: A multi-functional composition is disclosed as well as the preparation method and applications thereof. The composition contains a marine algae-derived material and an enzyme inhibitor. The marine algae-derived material is one from the group consisting of natural algal saccharide, alginic acid and alginate or is a mixture of several of them. The enzyme inhibitor is an inhibitor to the enzyme decomposing the material derived from marine algae.
    Type: Application
    Filed: February 21, 2018
    Publication date: July 19, 2018
    Inventors: Chenggang Zhang, Zhihui Li, Yu Li
  • Patent number: 9937198
    Abstract: A multi-functional composition is disclosed as well as the preparation method and applications thereof. The composition contains a marine algae-derived material and an enzyme inhibitor. The marine algae-derived material is one from the group consisting of natural algal saccharide, alginic acid and alginate or is a mixture of several of them. The enzyme inhibitor is an inhibitor to the enzyme decomposing the material derived from marine algae.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: April 10, 2018
    Assignees: Pinghu Sciscape Bio-Pharmaceutical Technology Co., Ltd., Beijing Bailening Biotechnology Co., Ltd., Suzhou Sciscape Bio-Pharmaceutical Technology Co. Ltd.
    Inventors: Chenggang Zhang, Zhihui Li, Yu Li
  • Patent number: 9630999
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: April 25, 2017
    Assignees: Suzhou Sciscape Biomedicine Science & Technology Co. Ltd., Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China
    Inventors: Chenggang Zhang, Junhuai Li, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li
  • Publication number: 20160129037
    Abstract: A multi-functional composition is disclosed as well as the preparation method and applications thereof. The composition contains a marine algae-derived material and an enzyme inhibitor. The marine algae-derived material is one from the group consisting of natural algal saccharide, alginic acid and alginate or is a mixture of several of them. The enzyme inhibitor is an inhibitor to the enzyme decomposing the material derived from marine algae.
    Type: Application
    Filed: May 30, 2014
    Publication date: May 12, 2016
    Applicants: Suzhou Sciscape Bio-Pharmaceutical Technology Co., Ltd., Pinghu Sciscape Bio-Pharmaceutical Technology Co., Ltd., Beijing Bailening Biotechnology Co. Ltd.
    Inventors: Chenggang ZHANG, Zhihui LI, Yu LI
  • Publication number: 20160060305
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Application
    Filed: November 13, 2015
    Publication date: March 3, 2016
    Applicants: SUZHOU SCISCAPE BIOMEDICINE SCIENCE & TECHNOLOGY CO. LTD., INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIB
    Inventors: Chenggang ZHANG, Junhuai LI, Yang XU, Yonghong WU, Weiguang LI, Yanchun ZHANG, Yan GAO, Zhihui LI
  • Patent number: 9259453
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: February 16, 2016
    Assignees: Suzhou Sciscape Biomedicine Science & Technology Co. Ltd., Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China
    Inventors: Chenggang Zhang, Junhuai Li, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li
  • Publication number: 20140248348
    Abstract: The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.
    Type: Application
    Filed: January 19, 2012
    Publication date: September 4, 2014
    Applicants: SUZHOU SCISCAPE BIOMEDICINE SCIENCE & TECHNOLOGY CO. LTD., PEOPLE'S LIBERATION ARMY OF CHINA
    Inventors: Chenggang Zhang, Junhuai Li, Yang Xu, Yonghong Wu, Weiguang Li, Yanchun Zhang, Yan Gao, Zhihui Li
  • Publication number: 20100028917
    Abstract: The invention discloses a Neuroglobin enzyme-linked immunosorbent assay kit and the use of it. The Neuroglobin enzyme-linked immunosorbent assay kit provided by the invention includes Neuroglobin polyclonal antibody, Neuroglobin monoclonal antibody and enzyme labeled antibody. Neuroglobin monoclonal antibody is produced through culturing hybridoma cells prepared by cell conjugation after inoculating mice with Neuroglobin antigen, whereas Neuroglobin polyclonal antibody is produced from animal antiserum after inoculating with Neuroglobin antigen.
    Type: Application
    Filed: April 30, 2005
    Publication date: February 4, 2010
    Applicants: Institute of Radiation Medicine, Academy of Military Science, People's Libration Army of China, Beijing Threesome Medicine Science and Technology Limited Company
    Inventors: Chenggang Zhang, Lihong Wang, Tingfang Chen, Aijia Shang, Yan Gao